NLS Clinical Trials

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Oncopeptides' clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway.

Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.

AnaCardio has announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).

The independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the study.

Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).